Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Retinoic acid fails to induce cell cycle arrest with myogenic differentiation in rhabdomyosarcoma.

Al-Tahan A, Sarkis O, Harajly M, Baghdadi OK, Zibara K, Boulos F, Dighe D, Kregel S, Bazarbachi A, El-Sabban M, Skapek SX, Saab R.

Pediatr Blood Cancer. 2012 Jun;58(6):877-84. doi: 10.1002/pbc.23246.

PMID:
21755593
2.

Differentiation of rhabdomyosarcoma cell lines using retinoic acid.

Barlow JW, Wiley JC, Mous M, Narendran A, Gee MF, Goldberg M, Sexsmith E, Malkin D.

Pediatr Blood Cancer. 2006 Nov;47(6):773-84.

PMID:
16283617
3.
4.

Influence of the level of gamma-glutamyltranspeptidase activity on the response of poorly and moderately differentiated rhabdomyosarcoma cell lines to all-trans-retinoic acid.

Palomares T, Castro B, del Olmo M, Iglesias A, Bilbao P, Alonso-Varona A.

Anticancer Drugs. 2006 Nov;17(10):1127-39.

PMID:
17075312
5.

All-trans retinoic acid arrests neuroblastoma cells in a dormant state. Subsequent nerve growth factor/brain-derived neurotrophic factor treatment adds modest benefit.

Cernaianu G, Brandmaier P, Scholz G, Ackermann OP, Alt R, Rothe K, Cross M, Witzigmann H, Tröbs RB.

J Pediatr Surg. 2008 Jul;43(7):1284-94. doi: 10.1016/j.jpedsurg.2008.01.007.

PMID:
18639684
6.

Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma.

Seitz G, Warmann SW, Vokuhl CO, Heitmann H, Treuner C, Leuschner I, Fuchs J.

Pediatr Surg Int. 2007 May;23(5):431-9.

PMID:
17211591
7.

The synthetic retinoid ST1926 as a novel therapeutic agent in rhabdomyosarcoma.

Basma H, Ghayad SE, Rammal G, Mancinelli A, Harajly M, Ghamloush F, Dweik L, El-Eit R, Zalzali H, Rabeh W, Pisano C, Darwiche N, Saab R.

Int J Cancer. 2016 Mar 15;138(6):1528-37. doi: 10.1002/ijc.29886.

PMID:
26453552
8.

All-trans-retinoic acid induces cell growth arrest in a human medulloblastoma cell line.

Chang Q, Chen Z, You J, McNutt MA, Zhang T, Han Z, Zhang X, Gong E, Gu J.

J Neurooncol. 2007 Sep;84(3):263-7.

PMID:
17453147
9.

The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation.

Taulli R, Bersani F, Foglizzo V, Linari A, Vigna E, Ladanyi M, Tuschl T, Ponzetto C.

J Clin Invest. 2009 Aug;119(8):2366-78. doi: 10.1172/JCI38075.

10.

Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics.

Cessna MH, Zhou H, Perkins SL, Tripp SR, Layfield L, Daines C, Coffin CM.

Am J Surg Pathol. 2001 Sep;25(9):1150-7.

PMID:
11688574
11.

Antitumor activity of the retinoid-related molecules (E)-3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid (ST1926) and 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) in F9 teratocarcinoma: Role of retinoic acid receptor gamma and retinoid-independent pathways.

Parrella E, Giannì M, Fratelli M, Barzago MM, Raska I Jr, Diomede L, Kurosaki M, Pisano C, Carminati P, Merlini L, Dallavalle S, Tavecchio M, Rochette-Egly C, Terao M, Garattini E.

Mol Pharmacol. 2006 Sep;70(3):909-24.

12.
13.

Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS.

Ciarapica R, Carcarino E, Adesso L, De Salvo M, Bracaglia G, Leoncini PP, Dall'agnese A, Verginelli F, Milano GM, Boldrini R, Inserra A, Stifani S, Screpanti I, Marquez VE, Valente S, Mai A, Puri PL, Locatelli F, Palacios D, Rota R.

BMC Cancer. 2014 Feb 27;14:139. doi: 10.1186/1471-2407-14-139.

14.

Differentiation therapy exerts antitumor effects on stem-like glioma cells.

Campos B, Wan F, Farhadi M, Ernst A, Zeppernick F, Tagscherer KE, Ahmadi R, Lohr J, Dictus C, Gdynia G, Combs SE, Goidts V, Helmke BM, Eckstein V, Roth W, Beckhove P, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende C.

Clin Cancer Res. 2010 May 15;16(10):2715-28. doi: 10.1158/1078-0432.CCR-09-1800.

15.

Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression.

Skrzypek K, Kusienicka A, Szewczyk B, Adamus T, Lukasiewicz E, Miekus K, Majka M.

Oncotarget. 2015 Oct 13;6(31):31378-98. doi: 10.18632/oncotarget.5145.

16.

Ara-C treatment leads to differentiation and reverses the transformed phenotype in a human rhabdomyosarcoma cell line.

Crouch GD, Kalebic T, Tsokos M, Helman LJ.

Exp Cell Res. 1993 Feb;204(2):210-6.

PMID:
8440318
17.
18.

Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells.

Saab R, Bills JL, Miceli AP, Anderson CM, Khoury JD, Fry DW, Navid F, Houghton PJ, Skapek SX.

Mol Cancer Ther. 2006 May;5(5):1299-308.

19.

The effect of the NF-kappa B inhibitors curcumin and lactacystin on myogenic differentiation of rhabdomyosarcoma cells.

Berger F, Büchsler I, Munz B.

Differentiation. 2012 Jun;83(5):271-81. doi: 10.1016/j.diff.2012.02.001.

PMID:
22469857
20.

Effect of all-trans retinoic acid on tissue dynamics of choriocarcinoma cell lines: an organotypic model.

Chiu PM, Feng HC, Benbrook DM, Ngan HY, Khoo US, Xue WC, Tsao SW, Chan KW, Cheung AN.

J Clin Pathol. 2006 Aug;59(8):845-50.

Items per page

Supplemental Content

Support Center